Published in Bone on April 09, 2011
Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop (2015) 1.11
Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity. Proc Natl Acad Sci U S A (2012) 1.09
Prodrugs of phosphonates and phosphates: crossing the membrane barrier. Top Curr Chem (2015) 1.00
Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality. Arthritis Res Ther (2012) 0.94
Synthesis and reactivity of alkyl-1,1,1-trisphosphonate esters. J Org Chem (2011) 0.90
Potent Triazole Bisphosphonate Inhibitor of Geranylgeranyl Diphosphate Synthase. ACS Med Chem Lett (2015) 0.90
Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab (2011) 0.89
Synthesis of isoprenoid bisphosphonate ethers through C-P bond formations: Potential inhibitors of geranylgeranyl diphosphate synthase. Beilstein J Org Chem (2014) 0.87
Human isoprenoid synthase enzymes as therapeutic targets. Front Chem (2014) 0.86
Bone-seeking TRAP conjugates: surprising observations and their implications on the development of gallium-68-labeled bisphosphonates. EJNMMI Res (2012) 0.86
Clinical development of neridronate: potential for new applications. Ther Clin Risk Manag (2013) 0.84
Bisphosphonate treatment for children with disabling conditions. PM R (2013) 0.83
Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function. Stem Cells (2015) 0.83
Bisphosphonates and cancer: what opportunities from nanotechnology? J Drug Deliv (2013) 0.81
A new motif for inhibitors of geranylgeranyl diphosphate synthase. Bioorg Med Chem (2016) 0.80
Live imaging of osteoclast inhibition by bisphosphonates in a medaka osteoporosis model. Dis Model Mech (2015) 0.79
Farnesyl pyrophosphate synthase modulators: a patent review (2006 - 2010). Expert Opin Ther Pat (2011) 0.79
Fluorescent Bisphosphonate and Carboxyphosphonate Probes: A Versatile Imaging Toolkit for Applications in Bone Biology and Biomedicine. Bioconjug Chem (2015) 0.78
Methylidynetrisphosphonates: Promising C1 building block for the design of phosphate mimetics. Beilstein J Org Chem (2013) 0.78
Measurement of Ototoxicity Following Intracochlear Bisphosphonate Delivery. Otol Neurotol (2016) 0.78
Induction of creatine kinase release from cultured osteoclasts via the pharmacological action of aminobisphosphonates. Springerplus (2015) 0.77
N-Oxide derivatives of 3-(3-pyridyl)-2-phosphonopropanoic acids as potential inhibitors of Rab geranylgeranylation. Bioorg Med Chem Lett (2015) 0.77
Effects of ibandronate sodium, a nitrogen-containing bisphosphonate, on intermediate-conductance calcium-activated potassium channels in osteoclast precursor cells (RAW 264.7). J Membr Biol (2014) 0.76
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. J Cancer Res Clin Oncol (2014) 0.76
The effects of 6-gingerol on proliferation, differentiation, and maturation of osteoblast-like MG-63 cells. Braz J Med Biol Res (2015) 0.76
The effect of bisphosphonates on the endothelial differentiation of mesenchymal stem cells. Sci Rep (2016) 0.76
Stereoselective Synthesis of Homoneryl and Homogeranyl Triazole Bisphosphonates. J Org Chem (2016) 0.76
Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study. Osteoporos Int (2016) 0.76
A Novel H2S-releasing Amino-Bisphosphonate which combines bone anti-catabolic and anabolic functions. Sci Rep (2017) 0.75
Difference in Bone Mineral Density Change at the Lateral Femoral Cortices according to Administration of Different Bisphosphonate Agents. J Bone Metab (2016) 0.75
Localization of Minodronate in Mouse Femora Through Isotope Microscopy. J Histochem Cytochem (2016) 0.75
Preparation of mixed trialkyl alkylcarbonate derivatives of etidronic acid via an unusual route. Beilstein J Org Chem (2012) 0.75
In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors. Biochem Pharmacol (2015) 0.75
Targeting Cancer Cells with a Bisphosphonate Prodrug. ChemMedChem (2016) 0.75
Two strategies for the synthesis of the biologically important ATP analogue ApppI, at a multi-milligram scale. Beilstein J Org Chem (2015) 0.75
Engineered Nanomedicine with Alendronic Acid Corona Improves Targeting to Osteosarcoma. Sci Rep (2016) 0.75
Low concentrations of zoledronic acid are better at regulating bone formation and repair. Intractable Rare Dis Res (2013) 0.75
Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation. Cell Death Dis (2017) 0.75
Evaluation of crystallographic orientation of biological apatite in vertebral cortical bone in ovariectomized cynomolgus monkeys treated with minodronic acid and alendronate. J Bone Miner Metab (2015) 0.75
Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats. Calcif Tissue Int (2017) 0.75
Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J Exp Clin Cancer Res (2017) 0.75
Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate. Calcif Tissue Int (2017) 0.75
Number and severity of prevalent vertebral fractures and the risk of subsequent vertebral fractures in Japanese women with osteoporosis: results from the minodronate trial. J Bone Miner Metab (2013) 0.75
Synthesis and biological evaluation of novel platinum complexes of imidazolyl-containing bisphosphonates as potential anticancer agents. J Biol Inorg Chem (2015) 0.75
Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents. J Med Chem (2002) 7.27
A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet (2006) 7.05
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet (2011) 5.56
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature (2012) 4.08
Protein production and purification. Nat Methods (2008) 3.97
Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study. Osteoporos Int (2012) 3.13
Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity. Nature (2007) 3.05
Critical residues for structure and catalysis in short-chain dehydrogenases/reductases. J Biol Chem (2002) 2.95
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A (2006) 2.73
Short-chain dehydrogenases/reductases (SDRs). Eur J Biochem (2002) 2.62
Denosumab and bisphosphonates: different mechanisms of action and effects. Bone (2010) 2.37
Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci (2007) 2.15
High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. Mol Cell Biol (2002) 1.95
Investigating the genetic association between ERAP1 and ankylosing spondylitis. Hum Mol Genet (2009) 1.95
Codon optimization can improve expression of human genes in Escherichia coli: A multi-gene study. Protein Expr Purif (2008) 1.82
The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. Chem Biol Interact (2008) 1.77
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. J Med Chem (2008) 1.74
Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PLoS One (2010) 1.71
Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res (2012) 1.70
Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. J Bone Miner Res (2012) 1.66
Crystal structures of the endoplasmic reticulum aminopeptidase-1 (ERAP1) reveal the molecular basis for N-terminal peptide trimming. Proc Natl Acad Sci U S A (2011) 1.64
Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength. PLoS Genet (2012) 1.64
Structural and mechanistic studies on γ-butyrobetaine hydroxylase. Chem Biol (2010) 1.62
Coenzyme-based functional assignments of short-chain dehydrogenases/reductases (SDRs). Chem Biol Interact (2003) 1.61
DNA polymerase beta fidelity: halomethylene-modified leaving groups in pre-steady-state kinetic analysis reveal differences at the chemical transition state. Biochemistry (2007) 1.61
Modifying the beta,gamma leaving-group bridging oxygen alters nucleotide incorporation efficiency, fidelity, and the catalytic mechanism of DNA polymerase beta. Biochemistry (2007) 1.61
Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci (2010) 1.60
The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci (2012) 1.60
Structural basis of fumarate hydratase deficiency. J Inherit Metab Dis (2011) 1.58
Short-chain dehydrogenase/reductase (SDR) relationships: a large family with eight clusters common to human, animal, and plant genomes. Protein Sci (2002) 1.54
A review on macrophage responses to biomaterials. Biomed Mater (2006) 1.50
Reversible sequestration of active site cysteines in a 2Fe-2S-bridged dimer provides a mechanism for glutaredoxin 2 regulation in human mitochondria. J Biol Chem (2006) 1.50
A homogeneous method for investigation of methylation-dependent protein-protein interactions in epigenetics. Nucleic Acids Res (2009) 1.49
(R)-beta,gamma-fluoromethylene-dGTP-DNA ternary complex with DNA polymerase beta. J Am Chem Soc (2007) 1.48
Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J Biol Chem (2012) 1.43
Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res (2010) 1.39
Nanomechanical properties and mineral concentration in articular calcified cartilage and subchondral bone. J Anat (2003) 1.38
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem (2008) 1.37
A new class of small molecule inhibitor of BMP signaling. PLoS One (2013) 1.36
Lamellar bone is an incremental tissue reconciling enamel rhythms, body size, and organismal life history. Calcif Tissue Int (2009) 1.34
Alpha,beta-difluoromethylene deoxynucleoside 5'-triphosphates: a convenient synthesis of useful probes for DNA polymerase beta structure and function. Org Lett (2009) 1.34
Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. Mol Endocrinol (2007) 1.33
The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding. J Biol Chem (2006) 1.32
Selective inhibitors of the JMJD2 histone demethylases: combined nondenaturing mass spectrometric screening and crystallographic approaches. J Med Chem (2010) 1.31
Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family. J Biol Chem (2011) 1.31
Structure of human phytanoyl-CoA 2-hydroxylase identifies molecular mechanisms of Refsum disease. J Biol Chem (2005) 1.29
Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients. PLoS One (2009) 1.29
Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry (2009) 1.28
Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: core biopsy studies and clinical correlations. J Bone Miner Res (2003) 1.28
Aldehyde dehydrogenase 7A1 (ALDH7A1) is a novel enzyme involved in cellular defense against hyperosmotic stress. J Biol Chem (2010) 1.28
A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism. Mol Endocrinol (2007) 1.27
A miniaturized screen for inhibitors of Jumonji histone demethylases. Mol Biosyst (2009) 1.27
Modulation of osteoclastogenesis by fatty acids. Endocrinology (2008) 1.25
Structural snapshots for the conformation-dependent catalysis by human medium-chain acyl-coenzyme A synthetase ACSM2A. J Mol Biol (2009) 1.25
Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein. EMBO J (2010) 1.25
RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol (2002) 1.25
Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet (2002) 1.23
A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. J Am Chem Soc (2011) 1.22
Fluorescently labeled risedronate and related analogues: "magic linker" synthesis. Bioconjug Chem (2008) 1.22
Halogenated beta,gamma-methylene- and ethylidene-dGTP-DNA ternary complexes with DNA polymerase beta: structural evidence for stereospecific binding of the fluoromethylene analogues. J Am Chem Soc (2010) 1.21
The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. Pharmacol Res (2010) 1.20
Circularly polarized light standards for investigations of collagen fiber orientation in bone. Anat Rec B New Anat (2003) 1.19
RAB26 and RAB3D are direct transcriptional targets of MIST1 that regulate exocrine granule maturation. Mol Cell Biol (2009) 1.19
Structures of the human GTPase MMAA and vitamin B12-dependent methylmalonyl-CoA mutase and insight into their complex formation. J Biol Chem (2010) 1.17
Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol Med (2013) 1.16
The crystal structure of human GLRX5: iron-sulfur cluster co-ordination, tetrameric assembly and monomer activity. Biochem J (2011) 1.15
High-level production and optimization of monodispersity of 11beta-hydroxysteroid dehydrogenase type 1. Biochim Biophys Acta (2004) 1.14
The human short-chain dehydrogenase/reductase (SDR) superfamily: a bioinformatics summary. Chem Biol Interact (2008) 1.13
Liver X receptors downregulate 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. Diabetes (2002) 1.12
Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone (2003) 1.12
Codon optimization reveals critical factors for high level expression of two rare codon genes in Escherichia coli: RNA stability and secondary structure but not tRNA abundance. Biochem Biophys Res Commun (2004) 1.12
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag (2010) 1.12
Characterization of human DHRS6, an orphan short chain dehydrogenase/reductase enzyme: a novel, cytosolic type 2 R-beta-hydroxybutyrate dehydrogenase. J Biol Chem (2005) 1.11
From flat foot to fat foot: structure, ontogeny, function, and evolution of elephant "sixth toes". Science (2011) 1.11
Molecular mechanisms underlying WOX1 activation during apoptotic and stress responses. Biochem Pharmacol (2003) 1.11